Prostate Cancer Clinical Trials in Myrtle Beach, South Carolina

12 studies are recruiting for prostate cancer in Myrtle Beach, South Carolina right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

   The purpose of the study is to demonstrate superiority of Saruparib (AZD5305) relative to placebo added to a standard radiation therapy (RT) + androgen deprivation therapy (ADT) regimen by assessment of metastases-free survival in participants with high-risk and very high-risk localised/locally adv…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Research Site, Myrtle Beach, South Carolina

   Locations

   346 in total

   Run by

   AstraZeneca

   See if you can join NCT06952803 on ClinicalTrials.gov

2. Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy

   The aim for this study is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Carolina Urologic Research Center, Myrtle Beach, South Carolina

   Locations

   34 in total

   Run by

   Clarity Pharmaceuticals Ltd

   See if you can join NCT06056830 on ClinicalTrials.gov

3. A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer

   Hormone therapy, or androgen deprivation therapy (ADT) is a standard way to treat prostate cancer. It works by reducing the amount of the main male sex hormone, testosterone in the body. Androgen receptor pathway inhibitors (ARPIs) are another type of hormone therapy. They either slow down how much…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Carolina Urologic Research Center, Myrtle Beach, South Carolina

   Locations

   54 in total

   Run by

   Astellas Pharma Global Development, Inc.

   See if you can join NCT07005154 on ClinicalTrials.gov

4. Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC

   The purpose of this study is to determine whether [225Ac]Ac-PSMA-617 (AAA817), given for up to 6 cycles at a dose of 10 Megabecquerel (MBq) +/- 10%, plus androgen receptor pathway inhibitor (ARPI), improves the radiographic progression free survival (rPFS) compared to investigator's choice of stand…

   Stage

   Phase 3

   Ages

   18 to 100

   Site

   Carolina Urologic Research Center, Myrtle Beach, South Carolina

   Locations

   95 in total

   Run by

   Novartis Pharmaceuticals

   See if you can join NCT06855277 on ClinicalTrials.gov

5. This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

   This study will explore whether a combination of the investigational drug mevrometostat (PF-06821497) and enzalutamide will work better than taking enzalutamide alone in participants with mCSPC who are ARPI naïve and have not yet received chemotherapy in the mCSPC setting.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Grand Strand Medical Center, Myrtle Beach, South Carolina

   Locations

   337 in total

   Run by

   Pfizer

   See if you can join NCT07028853 on ClinicalTrials.gov

6. A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs

   ANDROMEDA is a first-in-human, Phase I/II, open-label, multicenter study of AZD9750 in participants with metastatic prostate cancer. The trial evaluates safety, tolerability, pharmacokinetics/pharmacodynamics, and preliminary efficacy of AZD9750 as monotherapy and in combination with saruparib.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Research Site, Myrtle Beach, South Carolina

   Locations

   18 in total

   Run by

   AstraZeneca

   See if you can join NCT07336446 on ClinicalTrials.gov

7. Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer

   The primary objectives of this study are to evaluate the safety and tolerability of xaluritamig administered as monotherapy or in combination with an oral Gonadotropin-releasing Hormone (GnRH) antagonist in the neoadjuvant setting followed by radical prostatectomy, and to evaluate the feasibility a…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Carolina Urologic Research Center, Myrtle Beach, South Carolina

   Locations

   9 in total

   Run by

   Amgen

   See if you can join NCT06613100 on ClinicalTrials.gov

8. Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors

   This Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and preliminary clinical activity of MOMA-313 administered orally as a single agent or combination therapy in patients w…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Investigative Site #107, Myrtle Beach, South Carolina

   Locations

   18 in total

   Run by

   MOMA Therapeutics

   See if you can join NCT06545942 on ClinicalTrials.gov

9. PSMA PET Combined With MRI for the Detection of PCa

   This is an open label, longitudinal Phase 3 study of prostate specific membrane antigen (PSMA) positron emission tomography (PET) combined with magnetic resonance imaging (MRI) compared to standard of care (SOC) for the detection of prostate cancer (PCa).

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Atlantic Urology Specialists, Myrtle Beach, South Carolina

   Locations

   18 in total

   Run by

   Telix Pharmaceuticals (Innovations) Pty Limited

   See if you can join NCT07052214 on ClinicalTrials.gov

10. Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy

    This is a Phase II/III study. Patient population is adult participants with PSMA-positive mCRPC who had treatments with androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy and progressed on or after [177Lu]Lu-PSMA targeted therapy. Treatment of interest: the investigational tre…

    Stage

    Phase 2

    Ages

    18 to 100

    Site

    Carolina Urologic Research Center, Myrtle Beach, South Carolina

    Locations

    81 in total

    Run by

    Novartis Pharmaceuticals

    See if you can join NCT06780670 on ClinicalTrials.gov

11. A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer

    Medicines that reduce the amount of testosterone in the body are commonly used to treat prostate cancer. PRL-02 depot is a potential treatment for men with advanced prostate cancer. It is given by an injection into the muscle. Men with advanced prostate cancer can take part in this study. Their can…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Carolina Urologic Research Center, Myrtle Beach, South Carolina

    Locations

    25 in total

    Run by

    Astellas Pharma Global Development, Inc.

    See if you can join NCT04729114 on ClinicalTrials.gov

12. FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer

    The goal of this clinical trial is to learn if the vaccine FK-PC101 works to delay or prevent the return of prostate cancer in men who have had surgery to remove their prostate cancer. It will also learn about the safety of FK-PC101. The main questions it aims to answer are: Does FK-PC101 delay or …

    Stage

    Phase 2

    Ages

    Any age

    Site

    Carolina Urologic Research Center, Myrtle Beach, South Carolina

    Locations

    3 in total

    Run by

    Cellvax Therapeutics Inc

    See if you can join NCT06636682 on ClinicalTrials.gov